Moody's Corporation (MCO) — Investment Analysis
Analyst: Value-investing framework (Buffett / Munger / Klarman / Graham) Date: 2026-06-06 | Exchange: NYSE | Currency: USD Primary sources: SEC 10-K FY2023-FY2025, 10-Q Q1 2026, Q3/Q4 2025 + Q1 2026 earnings transcripts, AlphaVantage financial statements, 5-year daily prices
Executive Summary
Three-sentence thesis. Moody's is one half of a global credit-ratings duopoly (with S&P Global) that prints money — a regulatorily-entrenched toll booth on the world's $140-trillion-and-growing debt markets, earning 30% returns on invested capital with 45% operating margins and converting nearly a third of revenue to free cash flow. The business is demonstrably superb and the moat is among the widest in public markets, which is precisely why Li Lu's Himalaya Capital opened a new 1.61% position in Q1 2026 after the stock fell ~16% from its high. But at $451 — roughly 32x earnings and 32x EV/FCF — the price already discounts a decade of high-single-digit growth, leaving a probability-weighted expected return of only ~1.7%/yr and essentially no margin of safety; this is a wonderful business at a full-to-rich price.
Metrics Dashboard
| Metric | Value | Source |
|---|---|---|
| Price | $451.35 (2026-06-05) | AlphaVantage daily |
| Market cap | $78.8B | overview |
| Shares outstanding | 174.7M | overview / 10-K (177.3M issued) |
| Net debt | $4.97B (debt $7.35B − cash $2.38B) | 10-K FY2025 |
| Enterprise value | ~$83.8B | derived |
| FY2025 revenue | $7,718M (MIS $4,119M, MA $3,599M) | 10-K FY2025 |
| Operating margin (GAAP) | 44.8% (adj. ~50%+) | 10-K |
| Net income / GAAP diluted EPS | $2,459M / $13.67 | 10-K |
| FCF (FY2025) | $2,575M ($14.31/sh) | cash-flow.json |
| ROIC | 30.1% (5yr avg ~24%) | derived |
| ROE | 60.7% | derived |
| Net debt / EBITDA | 1.26x | derived |
| Interest coverage | 18.3x | derived |
| Dividend | $4.12 fwd (~0.9% yield), 22+ yrs paid, +10% in 2026 | dividends.csv / 10-K |
| P/E (TTM) | 32.4x | derived |
| EV/EBITDA | 21.3x | derived |
| FCF yield | 3.3% (on mkt cap) | derived |
| DCF fair value | $317–$452 (central $345–$399) | own model |
| 1-yr / 5-yr price return | −7.7% / +34.7% | price-summary |
Verdict: WAIT
A+ quality, T1 fortress, wide moat — but priced for perfection. Build the position on weakness, not at the top of the fair-value band.
- Accumulate below ~$370 (≈27x earnings, top of central DCF, ~0.6% gap to fair value)
- Strong Buy below ~$320 (≈23x earnings, where the 2022-style bear case is already priced and the margin of safety is real)
- At $451, the right action is patience. The 2022 drawdown ($235 low) shows MCO does go on sale when issuance freezes.
0. Why This Opportunity Is On My Desk
Li Lu's Himalaya Capital — one of the most concentrated, lowest-turnover, highest-conviction value funds on earth, and the manager Charlie Munger personally entrusted with his family's money — opened a new 1.61% position in MCO in Q1 2026. Li Lu does not chase. When he buys a great compounder, it is usually because (a) a temporary cloud has knocked the price down and (b) he intends to hold for a decade or more.
The cloud here is visible: MCO is down 7.7% over the trailing year and 16.4% from its 52-week high of $539, dragged by softer-than-feared bond-issuance volumes, a volatile geopolitical backdrop (the transcript references "the war in Iran," March spread-widening, and risk-on/risk-off windows), and a market that has rotated away from "expensive quality." Li Lu likely sees what this analysis confirms: the business is compounding intrinsic value at a mid-teens clip while the stock has gone sideways for a year — a setup that, at a low-enough price, becomes a fat pitch.
My job is not to mimic Li Lu but to reach my own verdict. His signal raises my conviction in the quality; it does not change the arithmetic of price. Both can be true: this is a business worth owning, and $451 is not yet the price at which to own it.
1. Phase 1 — Risk Analysis (Inversion)
"Invert, always invert." Before asking how MCO wins, ask how it loses.
1.1 Technological disruption — the AI question (the real bear case)
The single most-asked question on the Q1 2026 call was some version of: can AI replicate what Moody's does, and will regulators let Moody's use AI to do it faster? This is the crux.
- The threat: Large language models can already summarize filings, spread financials, and opine on creditworthiness. If "AI credit assessment" commoditizes, the analytical labor that Moody's sells could deflate in value, and new entrants could erode the duopoly.
- The reality check (from the transcript and 10-K): Credit ratings are not an information product; they are a regulatory license and a coordination mechanism. A rating from Moody's or S&P is embedded in bond covenants, insurance capital rules (NAIC), bank capital rules (Basel), money-market fund eligibility (SEC Rule 2a-7), and central-bank collateral frameworks. An AI's opinion has none of that institutional standing. CEO Robert Fauber: regulators have "heightened sensitivity around using AI to actually make decisions… who gets a loan… or what a credit rating might be," and the ratings committee "remains a human-in-the-loop discussion." AI is a cost lever for Moody's (it drove MIS adjusted margin to 66.7% on record issuance), not an existential one.
- Counter-counter: AI is unambiguously a bigger threat to Moody's Analytics (research, data, software) than to Ratings. MA's CreditView/Moody's View research and EDF-X are exactly the kind of content a capable model could approximate. Moody's defense is to become the trusted data layer for AI — hence the announced integrations putting "licensed Moody's intelligence" inside ChatGPT Enterprise, Claude (Anthropic), and Microsoft 365 Copilot via Model Context Protocol. This is smart, but it converts a sole-source moat into a "preferred-supplier" moat, which is thinner.
- P(materially impairs the franchise within 10 yrs) ≈ 10%. Impact if it happens: −40%. Expected loss ≈ −4%.
1.2 Regulatory / legal — the double-edged sword
- Tailwind: Regulation is the moat. The NRSRO designation (Nationally Recognized Statistical Rating Organization) is a near-impossible-to-replicate license; the EU/UK regimes (CRA Regulation, ESMA, FCA) similarly entrench incumbents. New regulation tends to raise the barrier.
- Headwind: The same regulators can attack the economics. Periodic proposals to move from the "issuer-pays" model (the rated company pays for the rating — an obvious conflict the 2008 crisis exposed) to "investor-pays" or a government-assignment system resurface every cycle. The EU AI Act (cited in the FY2025 10-K) adds compliance cost. Antitrust scrutiny of the duopoly is perennial.
- Litigation: Ratings agencies are repeat defendants (the 2008 RMBS settlements cost Moody's ~$864M to the DOJ/states in 2017). First-Amendment "opinion" defenses have held, but tail litigation risk is real.
- P(adverse structural regulation within 10 yrs) ≈ 12%. Impact: −30%. Expected loss ≈ −3.6%.
1.3 Competition
- Ratings is a stable duopoly: Moody's + S&P together ~80%+ of the market; Fitch a distant third; DBRS Morningstar, Kroll (KBRA) niche players. New entrants (Kroll) have taken share only in narrow structured-finance pockets. Pricing power persists: issuers pay because the market requires the big-two stamp, not because Moody's is cheapest.
- MA competes with Bloomberg, S&P Capital IQ, FactSet, MSCI, and a long tail of fintechs — a real, competitive market where Moody's must keep innovating.
- P(duopoly meaningfully cracks in Ratings within 10 yrs) ≈ 8%. Impact: −25%. Expected loss ≈ −2%.
1.4 Financial / operational — cyclicality is the honest risk
This is the risk the market is actually trading. MIS revenue is a transactional toll on bond issuance, and issuance is cyclical. In 2022, when the Fed shocked rates higher and the bond window slammed shut, MCO revenue fell from $6,218M (2021) to $5,468M (2022) — a 12% drop — operating income fell from $2,844M to $1,997M, and the stock fell ~50% to a $235 low. That is the playbook for the next deep entry point.
Mitigants: ~63% of FY2025 revenue is now recurring (over-time recognition $4,877M of $7,718M); MA is almost entirely subscription (98% recurring, $3.6B ARR, 95-97% retention); MIS itself has a recurring monitoring-fee base. The franchise is far more durable than a pure transaction shop. But a multi-quarter issuance freeze still hits earnings hard.
Balance sheet is a fortress: net debt $4.97B, net debt/EBITDA 1.26x, interest coverage 18.3x, $2.38B cash. Debt is termed-out senior notes. No financial-distress risk.
- P(multi-year issuance downturn within 10 yrs) ≈ 35% (it's a cycle, it will happen). Impact on price at a high entry: −30%. Expected loss ≈ −10.5%. This is the dominant risk and the reason to wait for a lower entry.
1.5 Management
CEO Robert Fauber (since 2021) is a long-tenured insider; CFO Noemie Heuland is credible and precise on the calls. Capital allocation is shareholder-friendly to a fault: ~110% of FCF returned via buybacks + a 22-year dividend-growth streak, with the buyback authorization just raised. Insider ownership is a healthy ~14% (per overview). The MA-CEO transition to Christina Kosmowski (June 2026) is a minor execution risk. No red flags.
- P(value-destructive management error within 10 yrs) ≈ 8%. Impact: −20%. Expected loss ≈ −1.6%.
1.6 Risk register (summary)
| # | Risk | P(event) | Impact | Expected loss |
|---|---|---|---|---|
| 1 | Cyclical issuance downturn (at a high entry) | 35% | −30% | −10.5% |
| 2 | AI commoditizes MA / thins the moat | 10% | −40% | −4.0% |
| 3 | Adverse structural regulation (issuer-pays reform) | 12% | −30% | −3.6% |
| 4 | Duopoly cracks in Ratings | 8% | −25% | −2.0% |
| 5 | Management / capital-allocation error | 8% | −20% | −1.6% |
| Sum of independent expected losses | ≈ −21.7% |
Tail risk (non-additive): a 2008-style systemic credit event would hit issuance and invite a legal/regulatory backlash simultaneously — a correlated −45% to −55% scenario. The 1.26x leverage means MCO survives it comfortably; the price would not.
2. Phase 2 — Financial Analysis
2.1 Five-year returns (DuPont) and ROIC vs WACC
| Year | Revenue ($M) | Op Inc ($M) | Net Inc ($M) | NOPAT ($M) | Invested Capital ($M) | ROIC | ROE |
|---|---|---|---|---|---|---|---|
| 2021 | 6,218 | 2,844 | 2,214 | 2,286 | 8,623 | 26.5% | 75.9% |
| 2022 | 5,468 | 1,997 | 1,374 | 1,559 | 8,245 | 18.9% | 54.5% |
| 2023 | 5,916 | 2,221 | 1,607 | 1,846 | 8,761 | 21.1% | 46.2% |
| 2024 | 7,088 | 2,971 | 2,058 | 2,267 | 8,903 | 25.5% | 57.7% |
| 2025 | 7,718 | 3,455 | 2,459 | 2,718 | 9,021 | 30.1% | 60.7% |
Invested capital = equity + total debt − cash. NOPAT = operating income × (1 − effective tax rate).
Read this table and the investment case becomes obvious. Even in the 2022 trough, ROIC was ~19% — more than double a reasonable 8-9% WACC. The five-year average ROIC of ~24% against an ~8.5% cost of capital is a **15-point economic-profit spread** that compounds shareholder value every single year. ROE looks supernormal (54-76%) only because relentless buybacks have shrunk the equity base; the underlying engine is the ROIC, and it is exceptional and rising.
DuPont intuition: high net margin (32%) × moderate asset turnover × high leverage-from-buybacks. The margin is the moat; the leverage is a choice, not a necessity.
2.2 Owner earnings
FY2025 operating cash flow $2,901M − capex $326M (capex is a trivial 4% of revenue — this is an asset-light toll booth) = FCF $2,575M ($14.31/share). There is negligible difference between GAAP earnings, owner earnings, and FCF here; the business converts ~93% of net income to free cash. Management guides FY2026 FCF to $2.8–3.0B.
2.3 My own DCF (explicit assumptions + sensitivity)
Base FCF $2,575M, 174.7M shares, net debt $4,967M, 10-year fade to a Gordon terminal (terminal growth 3%).
| Discount rate \ 10-yr growth | 8%→6% | 10%→7% | 12%→8% |
|---|---|---|---|
| 8.0% | $391 | $444 | $505 |
| 8.5% | $351 | $399 | $452 |
| 9.0% | $317 | $361 | $409 |
- Central fair value: $345–$399 (8.5–9.0% discount, ~9-10% growth fading to 7%).
- To justify today's $451 you must believe in roughly the top-right of the grid — ~10-12% FCF growth for a decade discounted at only 8% — a price-for-perfection assumption.
- The bear cell ($317, 9% discount / 8%→6% growth) is itself only ~30% below today; there is downside if growth disappoints.
2.4 Relative valuation
| MCO | S&P Global (peer) | Rationale | |
|---|---|---|---|
| P/E (TTM) | 32.4x | ~30-35x | Both trade as premium compounders |
| EV/EBITDA | 21.3x | ~high-teens/20x | Comparable |
| FCF yield | 3.3% | ~3% | Comparable |
MCO and SPGI move as a pair; neither is "cheap vs the other." On an absolute basis, a 3.3% FCF yield growing ~8-10% implies a ~11-13% long-run IRR if the multiple holds — but the multiple is near the high end of its own history, so multiple compression is the realistic risk, not expansion.
2.5 Capital allocation
- Buybacks: $1.6B treasury repurchases in 2025; authorization raised to $4.0B in Oct 2025 ($3,960M remaining); 2026 buyback guidance lifted to ~$2.5B. Management is buying its own stock at 32x — defensible for a 30%-ROIC compounder, but it is not opportunistic value-buying at these levels.
- Dividend: 22+ consecutive years paid, raised 10% for 2026 to ~$1.03/quarter ($4.12 annual); payout ~29% of FCF — ample room to keep growing.
- Net: returning ~110% of FCF. This is a "harvest" capital-allocation posture, appropriate for a low-reinvestment-need business.
3. Phase 3 — Moat Analysis
3.1 Moat sources, measured
- Regulatory / licensing (the deepest moat). NRSRO status; embedded in Basel bank capital, NAIC insurance capital, SEC 2a-7 money funds, ECB collateral rules, and countless bond covenants. Metric: MIS adjusted operating margin 66.7% (Q1 2026) on record $2T+ quarterly issuance — pricing power that only a licensed oligopoly produces.
- Network / standard effects. Issuers seek a Moody's rating because investors demand it; investors demand it because everyone uses it. A two-sided coordination standard. Metric: the big-two duopoly persists at ~80%+ share for decades despite Fitch, Kroll, DBRS trying.
- Brand / reputational capital. A 120-year track record (founded 1909) is the product. Trust is the asset; it cannot be bought, only accrued. Metric: survived the 2008 reputational crisis and emerged with share intact.
- Switching costs / data gravity (MA). Moody's Analytics embeds into lending, underwriting, KYC/compliance, and insurance workflows. Metric: 95-97% retention; $3.6B ARR; "primary view of risk." Once a bank wires Moody's into its credit-decisioning stack, ripping it out is a multi-year project.
- Cost / scale. The marginal cost of rating one more bond is near-zero; AI is pushing it lower. Metric: 44.8% GAAP / ~50%+ adjusted total-company operating margin; capex only 4% of revenue.
3.2 Durability test — what erodes this?
- Issuer-pays reform could compress margins (most credible structural threat — but politically hard; the system has survived every reform attempt since 2008).
- Disintermediation of bond markets by private credit — but Moody's is monetizing the shift: private-credit-related Ratings revenue grew 80%+ YoY in Q1 2026 as investors demand third-party assessments of private loans. The moat is migrating with the market, not being left behind.
- AI — a margin tailwind in Ratings, a competitive question in Analytics (addressed in §1.1).
Moat verdict: WIDE, durability 20+ years, trend stable-to-widening. The Ratings moat is among the most durable in any public company; the Analytics moat is narrower and must be actively defended. This is a textbook Buffett "toll bridge."
4. Phase 4 — Decision Synthesis
4.1 Probability-weighted 5-year outcome (from $451)
| Scenario | P | 5-yr FCF growth | Exit EV/FCF | Price | Annualized |
|---|---|---|---|---|---|
| Bull | 30% | 11% | 28x | $667 | +8.1% |
| Base | 45% | 8% | 25x | $513 | +2.6% |
| Bear | 20% | 3% | 18x | $279 | −9.2% |
| Severe | 5% | −2% | 14x | $158 | −18.9% |
| Weighted | ≈ +0.8% price + ~0.9% dividend = ~+1.7%/yr |
A ~1.7% expected annual return at today's price is below cash and far below a sensible ~10% hurdle. The distribution is negatively skewed at this entry: the base case barely beats inflation and the left tail is severe. This is the entire reason for the WAIT verdict — not a flaw in the business, but a price that pre-pays its quality.
4.2 What changes the math: a lower entry
The same model run from $370 lifts the expected return to ~5-6%/yr; from $320 to ~9-10%/yr with a genuine margin of safety. The 2022 cycle ($235 low) proves these prices are reachable when issuance freezes. The job is to wait for the pitch and then swing hard.
4.3 Position sizing
- Quality justifies a 3-4% target allocation at the right price.
- At $451: 0% new capital (WAIT). A starter tracking position is defensible for those who must own it, but the asymmetry favors patience.
- Below $370: begin accumulating to ~half-size.
- Below $320: complete the position aggressively.
4.4 Monitoring triggers
| Trigger | Action |
|---|---|
| Price < $370 | Begin accumulating (Accumulate zone) |
| Price < $320 | Strong Buy — complete position |
| Global bond issuance falls >15% YoY for 2+ quarters | Expect MIS earnings cut → likely the $320 entry |
| MA ARR growth slips below ~6% organic | Re-examine the Analytics moat / AI thesis |
| Concrete legislative move toward investor-pays / govt-assigned ratings | Reassess the structural moat immediately |
| MIS adjusted margin falls below ~58% structurally | Pricing-power erosion signal |
| Net debt/EBITDA rises above ~2.5x from a debt-funded deal | Capital-allocation discipline check |
5. Synthesis & Verdict
Moody's is a fortress: a wide-moat, 30%-ROIC, asset-light duopoly with 22 years of dividend growth, a 1.26x-levered balance sheet, and management that returns ~110% of a fast-growing free-cash-flow stream. Li Lu's new position is a well-earned vote of confidence in exactly this quality, and on weakness MCO is one of the best long-term holdings an investor can own.
But Rule #1 is don't lose money, and at $451 — 32x earnings, ~$345-399 central fair value, ~1.7%/yr expected return, negatively-skewed — there is no margin of safety. The correct response to a wonderful business at a rich price is not to reach; it is to wait. History (2022) shows this stock goes on sale roughly once a cycle. Verdict: WAIT. Accumulate below $370. Strong Buy below $320.
All financial figures sourced from MCO's SEC Form 10-K (FY2023-FY2025), Form 10-Q (Q1 2026), and Q1 2026 / Q3-Q4 2025 earnings transcripts, cross-checked against AlphaVantage financial statements and 5 years of daily prices. No analyst reports, price targets, or broker research were used; all valuation is independent. Yahoo Finance was not accessed.